Hester Biosciences Q1 FY27 results: Standalone PAT up 88 percent, consolidated PAT up 459 percent

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRevenue DeclineResults View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹2495.00

prior close

₹2526.40

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+0.0% vs market

Pharmaceuticals peers, median of 162sector-0.8%+0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.5

10m

+1.3

15m

+3.1

30m

+2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.6+0.0-0.8+0.3

Next day

-1.7+0.5-2.2-0.5-1.2

-2.9+1.9-4.7+0.2-3.1

-0.6+2.3-2.9+0.1-0.7

-2.0+3.6-5.6+0.5-2.5

-1.0+4.0-5.0+0.7-1.7

+0.2+4.0-3.8+1.4-1.2

15d

-3.6+4.9-8.4+0.4-4.0

-9.6+5.9-15.5+1.7-11.3

-13.4+4.8-18.2+3.0-16.5

-7.5pendingpending-2.4-5.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q1 FY27 revenue rose 14 percent to INR 726.6M; PAT jumped 88 percent to INR 147.1M. Poultry Healthcare grew 48 percent but Animal Healthcare fell 50 percent due to delayed government tenders. EBITDA margin expanded from 21 percent to 36 percent. Consolidated PAT rose 459 percent boosted by a INR 853.5M exceptional gain from a Gates Foundation loan modification (principal cut from USD 12M to USD 5M, interest waived). Consolidated revenue fell 8 percent on weaker Nepal and Africa operations.

Likely market impact

Strong standalone show with margin expansion; consolidated PAT inflated by a one-time exceptional gain from Gates Foundation loan restructuring.